Drugs / Tilpisertib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04130919 | Dec 2019 → Feb 2021 | ulcerative colitis | Gilead Sciences | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tilpisertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04130919 ↗ |
| Action | Inhibit | “Mitogen-activated protein kinase kinase kinase 8 inhibitor” CHEMBL4802154 ↗ |
| Modality | Small molecule | — CHEMBL4802154 ↗ |
| Route | Oral | “Tablets administered orally once daily” NCT04130919 ↗ |
| Target | MAP3K8 | “Mitogen-activated protein kinase kinase kinase 8 inhibitor” CHEMBL4802154 ↗ |